BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 22, 2008
View Archived Issues
Repros reports results from two studies of Proellex
Read More
Novel cancer therapeutics described in recent patent literature
Read More
MMRC initiates phase I/II study of elotuzumab in combination with Velcade
Read More
AGI presents an update on the ARDIS phase III program for Rezular in IBS-D
Read More
Lilly pays Galapagos EUR 1 million milestone payment under osteoporosis collaboration
Read More
Neuren completes recruitment and dosing in phase III trial of Glypromate
Read More
sanofi-aventis terminates development and commercialization agreement with Taiho for S-1
Read More
Biocon and Abraxis launch Abraxane in India for breast cancer
Read More
New treatment option for HIV infection disclosed in recent Genzyme patent
Read More
Recent Merck patent divulges new agents for bone disorders
Read More
Genentech reports on preclinical profile of MetMAb in pancreatic cancer models
Read More
Allos initiates phase II PDX study in transitional cell carcinoma of the bladder
Read More
Ambrilia starts phase I/II program of novel goserelin formulation in prostate cancer
Read More
BioCancell requests to begin phase I BC-819 trial in pancreatic cancer
Read More
Intranasal administration of testosterone shows benefit against depressive-like behavior
Read More
Curis selects Hsp90 inhibitor CUDC-305 as development candidate
Read More
MI-63 plus cisplatin effective combination against cisplatin-resistant head and neck cancer
Read More
Exelixis commences phase III XL-184 trial in medullary thyroid cancer
Read More
Vascular disrupting agent ASA-404 shows benefit in mouse model of head and neck cancer
Read More
Roche offers to acquire all outstanding shares of Genentech
Read More
Targacept begins phase IIb TC-5214 trial in major depressive disorder
Read More
AlphaVax initiates studies of prototype chlamydia vaccine
Read More
CSL Behring submits BLA to FDA for human fibrinogen concentrate for congenital bleeding
Read More
BMP Sunstone signs letter of intent to acquire Shengda for approximately USD 4.4 million
Read More
